Novo Nordisk, Wegovy

Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.
Novo Nordisk stock drops on STEP UP trial results
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in participants, and 18.7% regardless of treatment adherence.
Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug,
BioPharma Dive15m
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...
Healthline3d
How Much Does Wegovy Cost?
The price you pay for Wegovy (semaglutide) may depend on factors such as your dosage, whether you have health insurance coverage, and the pharmacy you use. Financial assistance may be available to ...
EurekAlert!8d
Semaglutide can have lifetime cost and health benefits for non-diabetic overweight or obese individuals with heart disease
For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Healthline3d
Side Effects of Wegovy: What You Need to Know
Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...
Getting back to normal after stopping Semaglutide
If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.
Wider benefits of Ozempic, Wegovy put pressure on Canadian insurers to expand drug coverage
Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...